Combination effect of recombinant human interleukin-1 alpha with antimicrobial agents.
AUTOR(ES)
Nakamura, S
RESUMO
Combination effects of recombinant human interleukin-1 alpha with ceftazidime, moxalactam, gentamicin, enoxacin, amphotericin B, miconazole, or an immunoglobulin preparation were evaluated in systemic infections with Pseudomonas aeruginosa, Klebsiella pneumoniae, and Candida albicans in normal mice and systemic infection with P. aeruginosa in mice with leukopenia induced by preadministration of cyclophosphamide. Synergistic effects were generally observed at interleukin-1 alpha doses as low as 1 to 30 ng per mouse with most combinations. The results show the possibility that recombinant human interleukin-1 alpha could be of help for treating obstinate infections not successfully treated with antimicrobial agents alone.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172759Documentos Relacionados
- Effects of recombinant human interleukin-6 alone and in combination with recombinant interleukin-1 alpha and tumor necrosis factor alpha on antibacterial resistance in mice.
- Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha.
- Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance.
- Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice.
- Fluoroquinolone antimicrobial agents.
